Entero Therapeutics, Inc., a pharmaceutical company, has been notified by The Nasdaq Stock Market LLC of non-compliance with a listing rule due to its failure to hold an annual meeting of stockholders in 2024.
The notice, received on January 7, 2025, indicates that the company did not meet the Nasdaq Listing Rule 5620(a), which requires an annual meeting within one year of the company's fiscal year end.
The company, which was previously known as First Wave BioPharma, Inc., AzurRx BioPharma (NASDAQ:ENTO), Inc., and BioPharma d'Azur, Inc., is now required to submit a plan to regain compliance by February 21, 2025. If Nasdaq accepts the plan, Entero Therapeutics may be granted an extension until June 30, 2025, to hold its annual meeting and return to compliance.
Entero Therapeutics has expressed its intention to convene the overdue annual meeting as soon as possible and is actively working on scheduling the event. The date of the meeting will be announced subsequently, and a proxy statement will be filed with the Securities and Exchange Commission in due course.
The information for this article was obtained from a recent 8-K filing with the Securities and Exchange Commission.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.